Eco-friendly resolution of spectrally overlapping signals of a combined triple-action over-the-counter pharmaceutical formulation for symptomatic management of COVID-19 pandemic: application to content uniformity testing

Table 4 Results of content uniformity testing of PAR, ASP and DIPH in Excedrin^® PM Headache caplets using the proposed spectrophotometric methods

Excedrin^® PM Headache caplet No.	% Recovery of the labeled claim
Excedrin^® PM Headache caplet No.	PAR D¹ method	ASP DWRS method	DIPH DD-RD method
1	100.21	99.20	104.46
2	99.21	98.83	101.57
3	99.71	100.88	101.75
4	100.59	99.46	102.10
5	101.85	98.67	101.57
6	102.60	102.00	99.41
7	102.96	101.47	98.68
8	103.23	100.80	101.57
9	99.14	101.58	99.41
10	100.59	99.57	100.61
Mean	101.01	100.24	101.11
SD	1.541	1.234	1.672
%RSD	1.526	1.231	1.654
Acceptance value (AV) ^a	3.70	2.95	4.01

ISSN: 2661-801X